Results 81 to 90 of about 6,944 (246)

Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP

Drug Design, Development and Therapy, 2023
Ping Fang,1 Zhengqin Ye,1 Ran Li,1 Dunmin She,2 Guannan Zong,1 Liya Zhang,1 Ying Xue,1 Keqin Zhang1 1Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, People’s Republic of China ...
Fang P, Ye Z, Li R, She D, Zong G, Zhang L, Xue Y, Zhang K   +7 more
doaj  

Review for "Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection"

, 2021

openalex   +2 more sources

Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations

Diabetology & Metabolic Syndrome
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes. However, previous studies have debated whether GLP-1RA use induces diabetic retinopathy (DR) in diabetic populations, and the ...
Baixuan Shen, Wanying Wang, Yuanhui Guo, Zilong Chen, Chuanxin Liu, Jiarui Huang, Ying Li   +6 more
doaj   +1 more source

Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review

Journal of Translational Medicine
Background Glucagon-like peptide-1 receptor agonist (GLP-1RAs) is a potent therapy for type 2 diabetes mellitus (T2DM) and obesity, especially in patients who are resistant to long-term insulin therapy.
Haifeng Yu, Maryam Davoudi, Sahar Sadegh-Nejadi, Xiaolei Miao, Molood Bagherieh, Reza Afrisham   +5 more
doaj   +1 more source

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the effects of individual SGLT2 inhibitors on preventing new‐onset proteinuria in patients with type 2 diabetes and preserved kidney function. Materials and Methods A target trial emulation was performed using commercially available databases, including health checkups and claims data, between April 1, 2014 and March 31, 2023 ...
Hiroki Nobayashi, Michihiro Satoh, Takuo Hirose, Shingo Nakayama, Yutaro Iwabe, Hideaki Hashimoto, Takahisa Murakami, Kouji Okada, Takefumi Mori, Hirohito Metoki   +9 more
wiley   +1 more source

Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio‐kidney‐metabolic (CKM) therapies (GLP‐1RA and SGLT2i) on kidney function in this population.
M. Luiza Caramori, Enrico Repetto, Christopher Perkins, Ambarish Pandey, Peter Rossing   +4 more
wiley   +1 more source

Review for "Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial"

, 2021
Luca De Nicola
openalex   +2 more sources

The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study

, 2022
Tingting Wu, Carlos King Ho Wong, Eric Ho Man Tang, Kenneth K. C. Man, Simon K.H. Wong, Ivan Chi Ho Au, Emily Tsui Yee Tse, Esther W. Chan, Eleanor Grieve, Olívia Wu, Enders K. Ng, Ian Chi Kei Wong   +11 more
openalex   +1 more source

Unimolecular GLP‐1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta‐Cell Survival and Glycaemic Regulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To characterise the metabolic benefits of a GLP‐1/apelin hybrid peptide, namely exendin‐4‐linker‐apelin (ELA), and associated acylated forms, including ELA‐Lys12(γGluPal), ELA‐Lys27(γGluPal) and ELA‐Lys38(γGluPal). Methods Concentration‐ and receptor‐dependent effects of the peptides on insulin secretion and beta‐cell turnover were ...
Ananyaa Sridhar, Ethan S. Palmer, Sarah L. Craig, Elzbieta Krason‐Kidzinska, Nigel Irwin, Finbarr P. M. O'Harte   +5 more
wiley   +1 more source

The Effect of SGLT-2 inhibitors and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis [PDF]

, 2022
Arjun Jogimahanti, Kevin A. Honan, Talha Ahmed, Luis León‐Novelo, Tarif Khair   +4 more
openalex   +1 more source